Summary of Bill S 2756: Affordable Inhalers and Nebulizers Act of 2025

Purpose and Intent

The Affordable Inhalers and Nebulizers Act of 2025 aims to improve access to essential respiratory medications, specifically inhalers and nebulizers, for individuals suffering from asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The bill seeks to address the rising costs of these medical devices and medications, which can be a barrier to treatment for many patients.

Key Provisions

The bill includes several important provisions designed to enhance affordability and accessibility:

• Price Regulation: The legislation proposes measures to regulate the pricing of inhalers and nebulizers, ensuring that they are affordable for all patients, particularly those with low income or without insurance.

• Insurance Coverage: It mandates that insurance plans cover a broader range of inhalers and nebulizers, reducing out-of-pocket costs for patients. This includes provisions for both brand-name and generic options.

• Patient Assistance Programs: The bill encourages the establishment of patient assistance programs to help individuals who may struggle to afford their medications, including subsidies or discounts.

• Research and Development Incentives: It includes incentives for pharmaceutical companies to invest in the development of new and improved inhalers and nebulizers, promoting innovation in respiratory care.

Affected Parties

The Affordable Inhalers and Nebulizers Act of 2025 would primarily benefit:

• Patients: Individuals with asthma, COPD, and other respiratory conditions would gain improved access to necessary medications and devices.

• Healthcare Providers: Doctors and healthcare professionals would be better equipped to prescribe affordable treatment options without the concern of cost barriers for their patients.

• Pharmaceutical Companies: While the bill imposes regulations, it also offers incentives for innovation, potentially benefiting companies that develop new products.

Procedural Aspects

• Introduced: The bill was introduced in the Senate on September 10, 2025.

• Legislative Actions: Following its introduction, the bill was read twice and referred to the Committee on Finance for further consideration.

• Companion Bill: There is a related bill, HR 5278, which serves as a companion measure in the House of Representatives, indicating bipartisan support for the initiative.

Conclusion

The Affordable Inhalers and Nebulizers Act of 2025 represents a significant step towards making essential respiratory medications more accessible and affordable for millions of Americans. By regulating prices, enhancing insurance coverage, and promoting innovation, the bill aims to alleviate the financial burden on patients and improve health outcomes for those with respiratory conditions.